Keywords: Breast, Breast, HR-Positive Breast Cancer,Nomogram ; Treatment Decisions
Motivation: Accurate recurrence risk stratification is crucial in HR+ breast cancer for guiding treatment. Multi-gene tests can be costly and have limitations, highlighting the need for a cost-effective, reliable alternative like MRI-based nomograms.
Goal(s): To evaluate the effectiveness of MRI-based nomogram in predicting CTS5 for adjuvant therapy decisions in HR+ breast cancer.
Approach: The study analyzed follow-up data of 106 patients and divided 303 patients into Training and validation cohorts. A nomogram was assessed using AUC and calibration metrics for CTS5 risk stratification.
Results: The nomogram demonstrated high discrimination and calibration in CTS5 classification, aligning with actual recurrence outcomes and supporting precision treatment planning.
Impact: This MRI-based nomogram enables personalized treatment for HR-positive breast cancer , thus offering a non-invasive, cost-effective approach for recurrence risk stratification and extended endocrine therapy decisions.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords